I just read this news twice. What do you make of it?

After an incredible piece of news just dropped, NOW is the perfect time to take another close look at this past idea… *Sponsored by Sica Media  Hey gang, it’s Jeff Bishop again.  If you recall, I brought up Genprex (Nasdaq: GPNX) as a “💡 Bright Idea” to you several weeks ago. The stock made a very nice move up at that time, and then quietly faded over the last few weeks. Right now, I think it is time to get GNPX back on your radar 📈 The reason is that a couple of days ago, GNPX issued what I thought was [bombshell news]( 💣, and I don’t think the market fully understood the gravity of it. While the stock has reacted positively to this news, it is only up around a dime from before this blockbuster news was released. You need to look into this more and decide what you think.  To me, this is one of the better news items this week, and I am actually shocked to see such a little reaction from the market… so far at least. So here is the deal… On Wednesday, GNPX said that it was granted “fast-track designation” by the FDA for its small-cell lung cancer drug candidate, REQORSA. If you read the release (emphases added), you’ll see that GNPX has some very interesting “friends”… The Company has previously received two other Fast-Track Designations for REQORSA, for REQORSA in combination with AstraZeneca (AZN) PLC's Tagrisso® in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso, and for REQORSA in combination with Merck & Co's (MRK) Keytruda® in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda. Later in the release, you’ll see this from GNPX’s Medical Officer: "This Fast Track Designation for the Acclaim-3 patient population is another validation of REQORSA's potential to treat lung cancer," said Mark Berger, MD, Chief Medical Officer at Genprex. "We are very excited to soon begin treating patients in the Acclaim-3 clinical trial, which positions REQORSA as a component of initial standard therapy for SCLC rather than as a treatment for relapse.” For a company of this size, I think this is absolutely game-changing news. I don’t have to tell you what the market size is for cancer-fighting drugs. The fact that GNPX is now on “fast track designation” means that they will find out if they are going to receive ultimate approval or not, sooner rather than later. I think that is exactly what shareholders want to see, too! [Watch this short video]( where a person (Jackie) in the actual trial study right now describes how this has impacted her life.   📺 I love this! ❤️ Let’s face it. We talk about stocks all of the time, but this is a real-world example of how a company is truly trying to change the lives of people for the better. Virtually all of us know someone who has been impacted by cancer, (many of us more than one) so this hits especially close to home. In case you haven’t been following the story since I brought it up a few weeks ago, GNPX has been spewing great news lately. Just look at all of the news headlines that they have been dropping in the last few weeks… Check out this [news release]( from earlier in the month Check this [one]( that just dropped the day before that… And this [strong news]( regarding Phase 2 approval the day before…    And then, just before that, they [announced]( an amazing program with a well-known medical university… Who knows what is next, but tiny GNPX is not just showing strong technical signals. It is paving the way with some really good news as well. A quick glance shows that even some analysts are taking notice. Look at the “buy” rating over at the [Wall Street Journal](… And then I found a report from a Wall Street firm that has a [price target]( over 265% higher than current levels… While I love trading biotech stocks because of the violent price moves that can happen (both good, and bad!), I am always cautious because of the risk that they will raise money by selling stock. These are small companies that typically are in desperate need of cash, after all. While the gains can be amazing when they work out, I know there could be losses on the other end, so I always make sure to play it safe and keep a stop in place to protect profits (if I have any.) GNPX is in a unique position, though. Look at how strong their [balance sheet]( is right now… Ok, $.35 of cash per share doesn’t sound like a lot for a mega-cap stock. But you should consider that GNPX is trading for just around $.80 a share right now. That means GNPX is sitting on nearly 40% of its entire value in just cash right now (as of their last public filing)! With the positive news flow, a great-looking technical set-up, and solid balance sheet, there is no question why [insiders]( have a positive outlook on GNPX as well, and have been quietly accumulating shares… Yes…GNPX could be a firecracker 🧨 Keep a close eye on GNPX today and make sure it is on your trading radar. With the huge news announcement they had yesterday, I am really excited about the prospects ahead of them! Also, make sure you check out their [website]( so you can get a good understanding of what the company does, as well as the risks and potential rewards. I never want anyone to buy a stock without fully understanding what they are getting into. By the way… 👉 Text “RAGE” to (888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone! To Your Success, *Please see disclosures below RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Manage your email subscriptions.]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. If you have a current active subscription with Bullseye Trades you will need to contact us if you want to cancel your subscription. Opting out of emails does not remove you from your service at Bullseye Trades.